Prospective analysis of 895 patients on a UK Genomics Review Board
| Autor: | Teresa Curiel, Helen Winter, Anjana Kulkarni, Michele Moschetta, Hendrik-Tobias Arkenau, Charles Swanton, Debra Haynes, Kevin Balbi, Nataliya Rozumna-Martynyuk, M. Kushnir, David Allan Moore, Martin Forster, Gabriel Mak, Philip Bennett, Mark Voskoboynik |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Cancer Research
medicine.medical_specialty Clinical tests Genomics lcsh:RC254-282 Prospective analysis Signalling & Oncogenes molecular oncology Ecology Evolution & Ethology medicine genomics Clinical significance Medical physics Uncertain significance Original Research Computational & Systems Biology Chemical Biology & High Throughput Human Biology & Physiology Molecular pathology business.industry Genome Integrity & Repair Tumour Biology lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Clinical trial molecular tumour board Editorial genomic medicine precision oncology oncology Medical genetics business Genetics & Genomics clinical genetics |
| Zdroj: | ESMO Open ESMO Open, Vol 4, Iss 2 (2019) |
| DOI: | 10.25418/crick.11380047.v1 |
| Popis: | Background The increasing frequency and complexity of cancer genomic profiling represents a challenge for the oncology community. Results from next-generation sequencing–based clinical tests require expert review to determine their clinical relevance and to ensure patients are stratified appropriately to established therapies or clinical trials. Methods The Sarah Cannon Research Institute UK/UCL Genomics Review Board (GRB) was established in 2014 and represents a multidisciplinary team with expertise in molecular oncology, clinical trials, clinical cancer genetics and molecular pathology. Prospective data from this board were collated. Results To date, 895 patients have been reviewed by the GRB, of whom 180 (20%) were referred for clinical trial screening and 62 (7%) received trial therapy. For a further 106, a clinical trial recommendation was given. Conclusions Numerous challenges are faced in implementing a GRB, including the identification of potential germline variants, the interpretation of variants of uncertain significance and consideration of the technical limitations of pathology material when interpreting results. These challenges are likely to be encountered with increasing frequency in routine practice. This GRB experience provides a model for the multidisciplinary review of molecular profiling data and for the linking of molecular analysis to clinical trial networks. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|